Literature DB >> 7441497

Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats.

A P Caputi, F Rossi, K Carney, H E Brezenoff.   

Abstract

The effects of intracerebroventricular (i.c.v.) injection of physostigmine and hemicholinium-3 (HC-3) on reflex bradycardia and tachycardia have been studied in unanesthetized rats. The reflex increases and decreases in heart rate were elicited by i.v. injection of norepinephrine and sodium nitroprusside, respectively. Physostigmine (5-10 micrograms) increased basal mean arterial pressure (MAP), reduced basal heart rate (HR), enhanced the reflex bradycardia and reduced reflex tachycardia. Physostigmine did not modify either the pressor effect of norepinephrine, the depressor effect of sodium nitroprusside or the responsiveness of peripheral muscarinic receptors. Pretreatment (i.c.v.) with atropine (0.3 micrograms) completely abolished the effect of physostigmine on MAP, HR, reflex bradycardia and reflex tachycardia. Pretreatment (i.c.v.) with mecamylamine (50 micrograms) did not modify the effect of the cholinesterase inhibitor on MAP, HR and reflex tachycardia, but inverted its effect on reflex bradycardia. Injection of HC-3 (20 micrograms i.c.v.) did not modify MAP, but reduced HR and inhibited both reflex bradycardia and reflex tachycardia. The HC-3 bradycardic effect started within minutes and lasted for about 1 hr, while the depressor effect on the reflexes began only after 15 min and continued for several hours. In addition, i.c.v. pretreatment with HC-3 completely abolished all the effects of physostigmine on MAP, HR, reflex bradycardia and reflex tachycardia. These results suggest that brain acetylcholine has a modulatory effect on baroreceptor reflexes. This modulation operates through muscarinic receptors in reflex tachycardia and through both muscarinic and nicotinic receptors in reflex bradycardia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7441497

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion.

Authors:  S Cuzzocrea; E Mazzon; L Dugo; A P Caputi; K Aston; D P Riley; D Salvemini
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Green tea polyphenol extract attenuates ischemia/reperfusion injury of the gut.

Authors:  Carmelo Muià; Emanuela Mazzon; Rosanna Di Paola; Tiziana Genovese; Marta Menegazzi; Achille P Caputi; Hisanori Suzuki; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-05       Impact factor: 3.000

3.  Protective effects of cyclosporin-A in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; G Squadrito; M Ferlito; B Deodato; M Arlotta; L Minutoli; G M Campo; A Bova; C Quartarone; G Urna; A Sardella; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; G Squadrito; G M Campo; M Ioculano; P Canale; F Rossi; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

5.  Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury.

Authors:  B Deodato; D Altavilla; G Squadrito; G M Campo; M Arlotta; L Minutoli; A Saitta; D Cucinotta; G Calapai; A P Caputi; M Miano; F Squadrito
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

6.  Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; G Squadrito; G M Campo; M Arlotta; C Quartarone; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock.

Authors:  P Canale; F Squadrito; D Altavilla; M Ioculano; B Zingarelli; G M Campo; G Urna; A Sardella; G Squadrito; A P Caputi
Journal:  Agents Actions       Date:  1994-10

8.  Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Authors:  Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Nimesh S A Patel; Rosanna Di Paola; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

9.  Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury.

Authors:  F Squadrito; M Ioculano; D Altavilla; B Zingarelli; P Canale; G M Campo; A Saitta; S Oriti; A Faggiotto; A P Caputi
Journal:  Agents Actions       Date:  1993-07

10.  Tyrphostin AG 126 reduces intestinal ischemia-reperfusion injury in the rat.

Authors:  Stefania Marzocco; Emanuela Mazzon; Aldo Pinto; Giuseppina Autore; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.